Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aspirin Plus Rivaroxaban Efficacy and Safety in Embolic Stroke of Undetermined Source: A Randomized, Placebo Controlled, Outcome Assessor Blind, Feasibility Study

NCT04273516 is registered in ClinicalTrials.gov with Mazandaran University of Medical Sciences as lead sponsor.

NCT NCT04273516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04273516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aspirin Plus Rivaroxaban Efficacy and Safety in Embolic Stroke of Undetermined Source: A Randomized, Placebo Controlled, Outcome Assessor Blind, Feasibility Study
Lead sponsor
Mazandaran University of Medical Sciences
Phase
Phase 2/3
Overall status
Completed
Start date
August 22, 2020
Completion date
April 30, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention, stroke